• helpdesk@Lucintel.com
  • |
  • +1 972 636 5056
  • |
  • Login
  • |
  • Register
  • |
...

Request the impact of COVID-19 in this market at no additional cost. Buy it today to get an advantage.

Request Now


The global cardiovascular drugs industry experienced average growth over the last five years and is expected to reach approximately US $174.8 billion in 2017, growing with a CAGR of 2.9% over the next five years. Top companies are making strategic acquisitions both to expand their global footprints and to take advantage of establi

shed business and expertise gained from acquired companies.

Lucintel, a leading global management consulting and market research firm, has conducted a competitive analysis of the leading global cardiovascular drugs companies and presents its findings in “Top Five Global Cardiovascular Drug Companies: Performance, Strategies, and Competitive Analysis.” The report provides detailed insights into the performance of the top five companies across the world. The analysis highlights the companies that are performing the best among the peer group, and in which areas, and therefore clarifies leading performance standards and the strengths and weaknesses of companies covered.

The global cardiovascular drugs industry is consolidated with all classes of drugs used for the treatment of cardiovascular diseases such as hypertension, high cholesterol, heart failure, acute stroke, abnormal rhythms of the heart, chest pain, and other cardiac disorders. The industry is dominated by the North America region. In this study, Lucintel thoroughly profiles the following five companies with detailed competitive assessments:
 
  • AstraZeneca            
  • Bristol-Myers Squibb
  • Novartis        
  • Pfizer            
  • Sanofi                                                
As indicted in the study, the thrombotic drugs segment is currently small, but holds great growth potential in the future. The launch and development of new products, incorporated with innovative technologies, will drive the growth as manufacturers look for ways to differentiate themselves from their competitors.

This study is intended to provide industry leaders with a competitive benchmarking of the world’s top five cardiovascular drugs companies. The study provides up-to-date information on the market share, profit margins, capabilities, and strategies of the leaders. It is designed to provide executives with strategically significant competitor information, data analysis and insight, critical to the development and implementation of an effective marketing and sales plan.

Cardiovascular drug companies competitive analysis report will save hundreds of hours of your own personal research time and will significantly benefit you in expanding your business opportunities in global cardiovascular drug companies industry. In today’s chaotic economy, you need every advantage that you can find to keep ahead in your business

In Lucintel's newest competitive research study on the world's cardiovascular drug companies, we thoroughly profile following five companies with detailed competitive assessments:
 
  • AstraZeneca            
  • Bristol-Myers Squibb
  • Novartis        
  • Pfizer
  • Sanofi

The detailed analysis of each company offers a critical view into key strategic areas, including:
 
  • Company overview          
  • Benchmarking (financial & market)
  • SWOT analysis         
  • Product positioning
  • Marketing strategy and tactics    
  • Corporate strategy
To make any investment, business or strategic decisions, you need adequate and timely information. Cardiovascular drug companies competitive analysis market report fulfills this core need. This is an indispensable reference guide for industry executives who are dealing with cardiovascular drug companies industry.

Some of the features of Top Five Global Cardiovascular Drug Companies: Performance, Strategies, and Competitive Analysis market intelligence report are:
 
  • Market size estimates in terms of (US $) value by segments of the global cardiovascular drug companies
  • Regional analysis: global cardiovascular drug companies breakdown by key regions (e.g., North America, Europe, APAC and ROW)
  • Market trends, drivers and forecasts
  • Competitive benchmarking of each players against their financial & market strength
  • Global and regional market share estimates for the top players
  • Product line overview and positioning of top players
  • SWOT analysis of the leaders
  • Marketing strategy and tactics    
  • Corporate strategy
  • More than 128 valuable figures/charts and 45 tables are provided in this report
     
 1. Executive Summary  

 2. Market Definition and Scope  

 3. Market Opportunity  

 4. Competitive Benchmarking (Financial and Market)  

 5. Company Profile on Following Parameters  

 6. Profiles on Following Companies  
 6.1. AstraZeneca PLC  
 6.2. Bristol Myers Squibb Company  
 6.3. Novartis AG  
 6.4. Pfizer Inc  
 6.5. Sanofi  

List of Figures
 
CHAPTER 3. Market Opportunity
Figure 3.1: Supply chain for cardiovascular drug market
Figure 3.2: Global cardiovascular drug industry annual trend 2006-2011 (US $B)
Figure 3.3: Global cardiovascular drug industry regional trend 2006-2011 (US $B)
Figure 3.4: Global cardiovascular drug industry regional trend 2006-2011 (%)
Figure 3.5: Global cardiovascular drug industry segment trend 2006-2011 (US $B)
Figure 3.6: Global cardiovascular drug industry segment trend 2006-2011 (%)
Figure 3.7: Global cardiovascular drug industry opportunity by region
Figure 3.8: Global cardiovascular drug industry opportunity by segment
    
CHAPTER 4.Competitive Benchmarking (Financial and Market)
Figure 4.1: Top five cardiovascular drug companies – financial benchmarking
Figure 4.2: Global top five cardiovascular drug companies gross profit and net profit analysis – 2011
Figure 4.3: Financial analysis – growth leadership quadrant (2011)
Figure 4.4: Market share of top players 2006
Figure 4.5: Market share of top players 2011
Figure 4.6: 2006 Market share analysis
Figure 4.7: 2011 Market share analysis
Figure 4.8: Global market share analysis 2011
Figure 4.9: Global market fragmentation 2011  
Figure 4.10: Market value North America: (US $B)
Figure 4.11: Market value Europe: (US $B)
Figure 4.12: Market value Asia Pacific: (US $B)
Figure 4.13: Market value Row: (US $B)
Figure 4.14: Regional revenue evaluation 2011(US $M)
Figure 4.15: Regional revenue evaluation 2011(%)
Figure 4.16: North American revenue trend for top players 2007-2011 (US $B)
Figure 4.17: Europe revenue trend for top players 2007-2011 (US $B)
Figure 4.18: Asia Pacific revenue trend for top players 2007-2011 (US $B)
Figure 4.19: Row revenue trend for top players 2007-2011 (US $B)
Figure 4.20: Lucintel triad - top five major players
 
CHAPTER 5. Company Profile of AstraZeneca
Figure 5.1: AstraZeneca’s revenue by business structure 2011
Figure 5.2: Lucintel Triad – AstraZeneca
Figure 5.3: Financial benchmarking AstraZeneca against top three and top five industry players’ average
Figure 5.4: Financial benchmarking of AstraZeneca against Top Five best
Figure 5.5: Global industry revenue trend Vs AstraZeneca (2007-2011) in US $B
Figure 5.6: Global market share trend for AstraZeneca (2007-2011) in (%)
Figure 5.7: North American industry revenue trend Vs AstraZeneca 2007-2011 in (US $B)
Figure 5.8: European industry revenue trend Vs AstraZeneca 2007-2011 in (US $B)
Figure 5.9: APAC industry revenue trend Vs AstraZeneca 2007-2011 in (US $B)
Figure 5.10: ROW industry revenue trend Vs AstraZeneca 2007-2011 in (US $B)
Figure 5.11: North American market share trend Vs AstraZeneca 2007-2011 in (%)
Figure 5.12: European market share trend Vs AstraZeneca 2007-2011 in (%)
Figure 5.13: APAC market share trend Vs AstraZeneca 2007-2011 in (%)
Figure 5.14: ROW market share trend Vs AstraZeneca 2007-2011 in (%)
Figure 5.15: AstraZeneca trend in R&D expenses 2007-2011 in US $B
Figure 5.16: AstraZeneca trend in R&D expenses Percentage of total revenue
Figure 5.17: Comparison of AstraZeneca SE R&D expenditure vs. top three & top five players   average 2011
Figure 5.18: AstraZeneca productivity 2007-2011 (US $M)
Figure 5.19: AstraZeneca capital investment value 2007-2011 (US $M)
Figure 5.20: Strategic execution
 
CHAPTER 6. Company Profile of Bristol-Myers Squibb
Figure 6.1: Bristol-Myers Squibb revenue by business structure 2011
Figure 6.2: Lucintel triad - Bristol-Myers Squibb
Figure 6.3: Financial benchmarking of Bristol-Myers Squibb against top three and top five industry players’ average
Figure 6.4: Financial benchmarking of Bristol-Myers Squibb against Top five best
Figure 6.5: Global industry revenue trend Vs Bristol-Myers Squibb (2007-2011) in (US $B)
Figure 6.6: Global market share trend for Bristol-Myers Squibb (2007-2011) in (%)
Figure 6.7: North American industry revenue trend Vs. Bristol-Myers Squibb 2007-2011 in (US $B)
Figure 6.8: European industry revenue trend Vs Bristol-Myers Squibb 2007-2011 in (US $B)
Figure 6.9: APAC industry revenue trend Vs Bristol-Myers Squibb 2007-2011 in (US $B)
Figure 6.10: ROW industry revenue trend Vs Bristol-Myers Squibb 2007-2011 in (US $B)
Figure 6.11: North American market share trend Vs Bristol-Myers Squibb 2007-2011 in (%)
Figure 6.12: European market share trend Vs Bristol-Myers Squibb 2007-2011 in (%)
Figure 6.13: APAC market share trend Vs DuPont 2007-2011 in (%)
Figure 6.14: ROW market share trend Vs DuPont 2007-2011 in (%)
Figure 6.15: Bristol-Myers Squibb trend in R&D expenses 2007-2011 in US $B
Figure 6.16: Bristol-Myers Squibb trend in R&D expenses Percentage of total revenue
Figure 6.17: Comparison of Bristol-Myers Squibb SE R&D expenditure Vs top three & top five players average 2011
Figure 6.18: Bristol-Myers Squibb productivity: 2007-2011 in (US $M)
Figure 6.19: Bristol-Myers Squibb capital investment value: 2007-2011 in (US $M)
Figure 6.20: Strategic execution
 
CHAPTER 7. Company Profile of Novartis
Figure 7.1: Novartis revenue by business structure 2011
Figure 7.2: Lucintel triad – Novartis
Figure 7.3: Financial benchmarking of Novartis against top three and top five industry players’ average
Figure 7.4: Financial benchmarking of Novartis against Top five best
Figure 7.5: Global industry revenue trend Vs Novartis (2007-2011) in (US $B)
Figure 7.6: Global market share trend for Novartis (2007-2011) in (%)
Figure 7.7: North American industry revenue trend Vs Novartis (2007-2011) in (US $B)
Figure 7.8: European industry revenue trend Vs Novartis l (2007-2011) in (US $B)
Figure 7.9: APAC industry revenue trend Vs Novartis (2007-2011) in (US $B)
Figure 7.10: ROW industry revenue trend Vs Novartis (2007-2011) in (US $B)
Figure 7.11: North American market share trend Vs Novartis (2007-2011) in (%)
Figure 7.12: European market share trend Vs Novartis l (2007-2011) in (%)
Figure 7.13: APAC market share trend Vs Novartis (2007-2011) in (%)
Figure 7.14: ROW market share trend Vs Novartis (2007-2011) in (%)
Figure 7.15: Novartis trend in R&D expenses 2007-2011 in US $B
Figure 7.16: Novartis trend in R&D expenses Percentage of total revenue
Figure 7.17: Comparison of Novartis R&D expenditure vs top three & top five players average 2011
Figure 7.18: Novartis productivity: 2007-2011 in (US $M)
Figure 7.19: Novartis capital investment value: 2007-2011 in (US $M)
Figure 7.20: Strategic execution
 
CHAPTER 8. Company Profile of Pfizer
Figure 8.1: Pfizer revenue by business structure 2011
Figure 8.2: Lucintel triad – Pfizer
Figure 8.3: Financial benchmarking of Pfizer against top three and top five industry players’ average
Figure 8.4: Financial benchmarking of Pfizer against Top five best
Figure 8.5: Global industry revenue trend Vs Pfizer (2007-2011) in (US $B)
Figure 8.6: Global market share trend for Pfizer (2007-2011) in (%)
Figure 8.7: North American industry revenue trend Vs Pfizer (2007-2011) in (US $B)
Figure 8.8: European industry revenue trend Vs Pfizer (2007-2011) in (US $B)
Figure 8.9: APAC industry revenue trend Vs Pfizer (2007-2011) in (US $B)
Figure 8.10: ROW industry revenue trend Vs Pfizer (2007-2011) in (US $B)
Figure 8.11: North American market share trend Vs Pfizer (2007-2011) in (%)
Figure 8.12: European market share trend Vs Pfizer (2007-2011) in (%)
Figure 8.13: APAC market share trend Vs Pfizer (2007-2011) in (%)
Figure 8.14: ROW market share trend Vs Pfizer (2007-2011) in (%)
Figure 8.15: Pfizer trend in R&D expenses 2007-2011 in US $B
Figure 8.16: Pfizer trend in R&D expenses Percentage of total revenue
Figure 8.17: Comparison of Pfizer R&D expenditure vs top three & top five players average 2011
Figure 8.18: Pfizer productivity: 2007-2011 in (US $M)
Figure 8.19: Pfizer capital investment value: 2007-2011 in (US $M)
Figure 8.20: Strategic execution
 
CHAPTER 9. Company Profile of Sanofi
Figure 9.1: Sanofi revenue by business structure 2011
Figure 9.2: Lucintel triad – Sanofi
Figure 9.3: Financial benchmarking of Sanofi against top three and top five industry players’ average
Figure 9.4: Financial benchmarking of Sanofi against Top five best
Figure 9.5: Global industry revenue trend Vs Sanofi (2007-2011) in (US $B)
Figure 9.6: Global market share trend for Sanofi (2007-2011) in (%)
Figure 9.7: North American industry revenue trend Vs Sanofi (2007-2011) in (US $B)
Figure 9.8: European industry revenue trend Vs Sanofi (2007-2011) in (US $B)
Figure 9.9: APAC industry revenue trend Vs Sanofi (2007-2011) in (US $B)
Figure 9.10: ROW industry revenue trend Vs Sanofi (2007-2011) in (US $B)
Figure 9.11: North American market share trend Vs Sanofi (2007-2011) in (%)
Figure 9.12: European market share trend Vs Sanofi (2007-2011) in (%)
Figure 9.13: APAC market share trend Vs Sanofi (2007-2011) in (%)
Figure 9.14: ROW market share trend Vs Sanofi (2007-2011) in (%)
Figure 9.15: Sanofi trend in R&D expenses 2007-2011 in US $B
Figure 9.16: Sanofi trend in R&D expenses Percentage of total revenue
Figure 9.17: Comparison of Sanofi R&D expenditure vs top three & top five players average 2011
Figure 9.18: Sanofi productivity: 2007-2011 in (US $M)
Figure 9.19: Sanofi capital investment value: 2007-2011 in (US $M)
Figure 9.20: Strategic execution
 
 
List of Tables
CHAPTER 3. Market Opportunity
Table 3.1: Industry parameters of global cardiovascular drug industry
Table 3.2: Relative market attractiveness by region
Table 3.3: Regional revenue growth rate
Table 3.4: Segment revenue growth rate
 
CHAPTER 4. Competitive Benchmarking (Financial and Market)
Table 4.1: Financial benchmarking of top five global cardiovascular drug companies
Table 4.2: Key financial parameters for top five cardiovascular drug companies
Table 4.3: Regional revenue (US $M)
Table 4.4: Regional revenue (%)
Table 4.5: Competitors based on markets served
Table 4.6: Lucintel triad - Top five major players
 
CHAPTER 5. Company Profile of AstraZeneca
Table 5.1:  Market served: AstraZeneca
Table 5.2:  Lucintel triad – AstraZeneca
Table 5.3:  Financial Benchmarking of AstraZeneca against best and against Top three and Top five industry players’ average
Table 5.4:  Strategic execution – product positioning by segment
Table 5.5:  Strategic execution – perceived customer value / quality
Table 5.6:  Strategic execution – promotion / communications
Table 5.7:  Strategic execution – product distribution by region
 
CHAPTER 6. Company Profile of Bristol-Myers Squibb  
Table 6.1: Market served – Bristol-Myers Squibb  
Table 6.2: Lucintel triad – Bristol-Myers Squibb  
Table 6.3: Financial benchmarking of Bristol-Myers Squibb against best and against Top three and Top five industry players’ average
Table 6.4: Strategic execution – product positioning by segment
Table 6.5: Strategic execution – perceived customer value / quality
Table 6.6: Strategic execution – promotion / communications
Table 6.7: Strategic execution – product distribution by region
 
CHAPTER 7. Company Profile of Novartis
Table 7.1: Market served – Novartis
Table 7.2: Lucintel triad – Novartis
Table 7.3: Financial benchmarking of Novartis against best and against Top three and Top five industry players’ average
Table 7.4: Strategic execution – product positioning by segment
Table 7.5: Strategic execution – perceived customer value / quality
Table 7.6: Strategic execution – promotion / communications
Table 7.7: Strategic execution – product distribution by region
 
CHAPTER 8. Company Profile of Pfizer
Table 8.1: Market served – Pfizer
Table 8.2: Lucintel triad – Pfizer
Table 8.3: Financial Benchmarking of Pfizer against best and against Top three and top five industry players’ average
Table 8.4: Strategic execution – product positioning by segment
Table 8.5: Strategic execution – perceived customer value / quality
Table 8.6: Strategic execution – promotion / communications
Table 8.7: Strategic execution – product distribution by region
 
CHAPTER 9. Company Profile of Sanofi
Table 9.1: Markets Served – Sanofi
Table 9.2: Lucintel triad – Sanofi
Table 9.3: Financial Benchmarking of Sanofi against best and against Top three and top five industry players’ average
Table 9.4: Strategic execution – product positioning by segment
Table 9.5: Strategic execution – perceived customer value / quality
Table 9.6: Strategic execution – promotion / communications
Table 9.7: Strategic execution – product distribution by region
 
.

Buy full report or by chapter as follows

Price by License Type:
[-] Hide Chapter Details
[Chapter Number] [Chapter Name] [Chapter Number Of Pages] [Chapter Price]
Title/Chapter Name Pages Price
Full Report: Cardiovascular Drug Companies Analysis Full Report $ 1,980
More than 128 valuable figures/charts and 45 tables are provided in this report
 
Lucintel has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets / applications and served 1,000+ clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
  • In-depth interviews of the major players in this market
  • Detailed secondary research from competitors’ financial statements and published data
  • Extensive search of published works, market and database information with industry news, company press releases, and customer intentions
  • A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted in the supply chain of this market to estimate market share, market size, trends, drivers, challenges and forecasts in the market. Below is a brief summary of primary interviews conducted by both job function and region.


Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis on it. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of the Lucintel research process.

 

Please sign in below to get report brochure - Cardiovascular Drug Companies Analysis.

At Lucintel, we respect your privacy and maintain the confidentiality of information / data provided by you
(Please enter your corporate email. * These fields are mandatory )